您的位置: 印度药房网 > 医药大数据 > 结直肠癌 >
瑞格非尼

瑞格非尼

【 药品别名 】 拜万戈 瑞戈非尼 Stivarga regorafenib

【药品简介】 瑞戈菲尼可广泛抑制与血管生成和肿瘤发生相关的激酶

【适应症状】 处方药。肝细胞肝癌:用于前期使用过索拉菲尼的肝细胞肝癌。转移性结直肠癌:用于治疗既往曾用含氟嘧啶、奥沙利铂、伊立替康方案的化疗或抗VEGF药物或抗EGFR药物(如果患者是RAS野生型)的转移性结直肠癌。胃肠道间质性肿瘤:用于治疗既往曾用伊马替尼和舒尼替尼药物的,局部进展的、无法切除的或转移性胃肠道间质性肿瘤(GIST)

印度瑞格非尼(拜万戈 瑞戈非尼 Stivarga regorafenib)价格,正品图片,治疗结直肠癌药物, 购买瑞格非尼请到印度药房官方网站进行购买 【印度药房大全目录】

资料发布时间:2018-10-30 14:50:00 资料更新时间:2019-11-12 09:08:17

【印度瑞格非尼(拜万戈 瑞戈非尼 Stivarga regorafenib)说明书】

【作用机制】   

拜万戈瑞戈非尼)是一个多激酶抑制剂,通过抑制肿瘤血管生成、肿瘤细胞新生、维持肿瘤微环境的因素,来抑制肿瘤生长。包括VEGF受体1-3,KIT,PDGFR-alpha,PDGFR-beta,RET,FGFR1和2,TIE2,DDR2,TrkA,Eph2A,RAF-1,BRAF,BRAF-V600E,SAPK2,PTK5和Abl。
 
【副作用】 

乏力,食欲减轻,皮肤反应,腹泻,口腔黏膜炎,体重减轻,感染,高血压,发音困难等。

【给药方法】

口服,每天定时服药。低脂饮食后,用水吞服。

【参考用法】

口服,160mg,每天一次,28天为一个周期,在前21天服用(服用21天,休息7天),直至疾病进展或不可接受的毒性。

【注意事项】

使用瑞格菲尼后,因副反应可调整剂量:在原有基础上可每次减少一片药:40mg。每日最少推荐剂量为80mg。
瑞格非尼

【在以下情况时应当永久停止使用瑞格菲尼】

使用80mg的剂量时,仍不能耐受。

任何情况下发生ALT或AST升高至正常值上限的20倍以上时。

任何情况下发生ALT或AST升高至正常值上限的3倍以上,且伴有胆红素高于正常值上限值的2倍。

即使将剂量减少至120mg,再次发生ALT或AST升高至正常值上限的5倍以上。

对于任何4级副反应,只有当潜在的益处大于风险时才能继续使用该药。

Regorafenib uses

Regorafenib is used in the treatment of cancer of colon and rectum.

How regorafenib works

Regorafenib is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Common side effects of regorafenib

Rash, Weakness, Low blood platelets, Difficulty in speaking, Haemorrhage, Vomiting, Pain, Nausea, Infection, Hair loss, Fever, Anemia (low number of red blood cells), Diarrhea, High blood pressure, Decreased appetite, Mucosal inflammation, Stomatitis (Inflammation of the mouth)

Regorafenib

生物活性

产品描述

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).

靶点活性

Kit,7 nM (cell free)

Raf-1,2.5 nM (cell free)

RET,1.5 nM (cell free)

VEGFR1,13 nM (cell free)

VEGFR2,4.2 nM (cell free)

B-Raf (V600E),19 nM (cell free)

实验溶液

30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL

体外活性

Regorafenib potently inhibited a distinct set of kinases, including the angiogenic and stromal RTKs VEGFR1-3, TIE2, FGFR1 and PDGFR-b (IC50s: 4-311 nM), and the oncogenic RTKs KIT and RET, along with the intracellular signaling kinases c-RAF/RAF-1 and BRAF and its V600E mutant (IC50s: 1.5-28 nM). Regorafenib potently inhibited VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells (IC50: 3 nM). In HAoSMCs, regorafenib inhibited PDGFR-b autophosphorylation after stimulation with PDGF-BB (IC50: 90 nM) [1]. Regorafenib caused a concentration-dependent decrease in Hep3B cell growth (IC50: 5 μM). PLC/PRF/5 cells were similar in their responses to Hep3B cells, but HepG2 cells were more sensitive (IC50: 1 μM) [2].

体内活性

Treating tumor-bearing rats with a single oral dose of regorafenib at 10 mg/kg caused a significant decrease in tumor perfusion and extravasation of the contrast agent. A significant reduction of the normalized IAUC360 was observed by 10 hr after regorafenib treatment and persisted for up to 2 days when compared with vehicle. Regorafenib dosed qd orally inhibited tumor growth in a dose-dependent manner in multiple xenograft models, including models derived from CRC (Colo-205), BC (MDA-MB-231) and RCC (786-O) tumors. Regorafenib (10–100 mg/kg) effectively inhibited the growth of the Colo-205 xenografts, reaching a TGI of ~75% at day 14 at the 10 mg/kg dose [1]. In murine xenograft models, oral regorafenib, M-2, and M-5 significantly inhibited tumor growth versus controls. Total peak plasma drug concentrations and exposure to M-2 and M-5 in mice after repeated oral dosing with regorafenib 10 mg/kg/day were comparable to those in humans [3].

激酶实验

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFR-b (aa561–aa1106), RAF-1 (aa305–aa648) and BRAFV600E (aa409–aa765) kinase domains were performed as previously described. Initial in vitro kinase inhibition profiling was performed at a fixed 1 μM compound concentration under Millipore standard conditions [10 μM adenosine-50’- triphosphate (ATP) concentration]. Inhibitory concentration of 50% (IC50) values were determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition was measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.

细胞实验

Each cell line was seeded at 0.3×10^5 cells/2ml of DMEM containing 10% FBS in 35 mm tissue culture dishes. The cells were incubated for 24 h to allow attachment, and then the medium was replaced by fresh culture medium containing Regorafenib at increasing concentrations (1 μM, 2.5 μM, 5 μM, 7.5 μM and 10 μM). In these experimental conditions, the cells were allowed to grow for 72 or 96 h. Time-course experiments on Hep3B cells were performed with 7.5 μM of Regorafenib at short (15, 60, 180 min.), middle (24, 48, 72 and 96 h) or long times (up to seven days). When the cells were treated for long times the drug was replaced with a fresh one. Each experiment included a control with the equivalent concentration of DMSO (solvent control) as the one used for adding Regorafenib. Each experiment was performed in triplicate and repeated 3 times. Subsequent analyses were performed at specific Regorafenib concentrations and incubation times [2].

细胞系: GIST 882 and TT cells

动物实验

Female athymic NCr nu/nu mice, kept in accordance with Federal guidelines, were subcutaneously inoculated with 5×10^6 Colo-205 or MDAMB-231 cells or implanted with 1 mm^3 786-O tumor fragments. When tumors reached a volume of ~100 mm^3, regorafenib or vehicle control was administered orally qd×21 in the 786-O model, and qd×9 in the Colo-205 and MDA-MB231 models, respectively, at doses of 100, 30, 10, and 3 mg/kg. Paclitaxel was administered intravenously at 10 mg/kg in ethanol/Cremophor ELV/saline (12.5%/12.5%/75%) every 2 days×5. Tumor size (volume) was estimated twice weekly (l×w^2)/2, and the percentage of tumor growth inhibition (TGI) was obtained from terminal tumor weights (1-T/C100). Mice were weighed every other day starting from the first day of treatment. The general health status of the mice was monitored daily [1].

动物模型:Feathymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O

化学信息

分子量

482.82

分子式

C21H15ClF4N4O3

CAS

755037-03-7

溶解度

DMSO: 90 mg/mL (186.4 mM)

Ethanol: <1 mg/mL

Water: <1 mg/mL

( < 1 mg/ml refers to the product slightly soluble or insoluble )

储存条件

store at -80°C

备注

For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

配制溶液

  1 mg 5 mg 10 mg
1 mM 2.071 ml 10.356 ml 20.712 ml
5 mM 0.414 ml 2.071 ml 4.142 ml
10 mM 0.207 ml 1.036 ml 2.071 ml
50 mM 0.041 ml 0.207 ml 0.414 ml

参考文献
 
1. Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.
2. Carr BI, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228(2), 292-297.
3. Zopf D, et al. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. 2016 Nov;5(11):3176-3185.
注:本站瑞格非尼(拜万戈 瑞戈非尼 Stivarga regorafenib)药品说明均来自于官方,请咨询您的治疗医生了解更多细节。如需药品请到正规印度药房进行购买
上一篇:没有了 下一篇:格列卫
瑞格非尼相关药品
瑞格非尼
瑞格非尼

处方药。肝细胞肝癌:用于前期使用过索拉菲尼的肝细胞肝癌。转移性结直肠癌:用于治疗既往曾用含氟嘧啶、奥沙利铂、伊立替康...

格列卫
格列卫

处方药。用于治疗费城染色体阳性的慢性髓性白血病(Ph+CML)的慢性期、加速期或急变期;用于治疗难治复发成人费城染色体阳性的...

瑞格非尼资讯
瑞戈非尼的耐药
瑞戈非尼的耐药

瑞戈非尼是一种小分子多激酶抑制剂,适用于多种肿瘤患者的治疗。雷格非尼布还被批准适应多个消化系统的恶性肿瘤,包括直肠癌...

瑞戈非尼的好处
瑞戈非尼的好处

尽管目前治疗结直肠癌的药物众多,但是对于治后出现疾病进展的晚期患者来说,仍面临无药可救的地步...

瑞戈非尼怎么吃
瑞戈非尼怎么吃

瑞戈非尼是一个小分子多激酶抑制剂,适应于多种肿瘤患者的治疗。...

瑞戈非尼的注意事项
瑞戈非尼的注意事项

瑞戈非尼一种新型的多激酶抑制剂,通过抑制促进肿瘤生长的多种蛋白激酶,靶向肿瘤细胞形成、肿瘤血管生成和肿瘤微环境信号的...

结直肠癌和肝癌——瑞戈非尼
结直肠癌和肝癌——瑞戈非尼

瑞戈非尼是一种多激酶抑制剂,可通过抑制肿瘤血管生成来抑制肿瘤生长。 ...

瑞戈非尼的二线治疗
瑞戈非尼的二线治疗

瑞戈非尼是一种具有多靶点的新型抗癌药物。它有许多靶标,包括VEGFR 1、VEGFR 2、VEGFR 3、Ti-1、Ti-2、RAF-1、BRAF、BRAFV 600、KIT、RET、P...

拜万戈的价格
拜万戈的价格

对于许多癌症患者来说,通过服用药物延长生命的能力对癌症患者来说是一个福音。...

二代肝癌药,瑞戈非尼
二代肝癌药,瑞戈非尼

TKIs 作为一类分子靶向药物,已成为当前抗肝癌研究的主流趋势之一。...

吃瑞戈非尼后,怎样检测血压
吃瑞戈非尼后,怎样检测血压

瑞戈非尼等抗血管生成类靶向药引起高血压的机制比较复杂,发生率约为15%~28%。...

印度瑞戈非尼的用法和购买渠道
印度瑞戈非尼的用法和购买渠道

瑞戈非尼虽然在国内已经上市了,但是价格却比较高,对于普通患者家庭来说,是不小的负担。因此有更多的患者将目光投向了印度...

瑞格非尼视频
什么是白血病?
什么是白血病?

白血病是一类造血干细胞恶性克隆性疾病...

中医与免疫治疗有什么关系?
中医与免疫治疗有什么关系?

中医有一句话叫做正气存内邪不可干,正气就包括了阴阳的平衡,气血、脏腑功能的平衡...

宝宝得了白血病还有救吗?
宝宝得了白血病还有救吗?

宝宝得了白血病不光有救,也有可能完全治愈,...

儿童白血病如何治疗?
儿童白血病如何治疗?

儿童白血病的治疗原则为早期诊断、早期治疗,有间歇、交替用药的方式,并坚持长期的治疗,预防复发。...

药房目录大全

Pharmacy Catalogue